No Morningstar update, but think HC before FDA EUA @Boudi... not worried about Morningstar.... don't even subscribe. Don't believe in 5 tier projections, it's a way they hedge their bets.
However, I do think HC may come in faster than FDA EUA. But who really knows?!?!?!
Here's my thinking...
(1) THRM is a Canadian company with a Canadian COVID-19 test product, versus so many US, Chinese, Korean, etc. tests - PCR, Antigen and Antibody/Serology - that HC has approved.
(2) HC has approved 1 saliva-based Antigen Test (PCL) and 45 other Antigen nasal-based tests. I think AcuVid will show better than PCL, maybe not in PPA performance but all the other tests required for FDA EUA and not with HC.
(3) Covid-19 is on the rise in Canada and World, specifically Omicron, and Acuvid U.S. Clinical Study was conducted during Delta & Omicron waves,
(4) FDA required mouth-borne viruses/bacteria cross reactivity tests on probably a dozen or so viruses/bacteria, as well as nasal-borne virus/bacteria, HC application doesn't look as strict..so those mouth-borne cross reactivity studies offer HC more insurance on Acuvid's performance and test quality,
(5) timelines from HC Submission/HC Review/HC Approval are pretty consistent...just need to look at the numbers for all their tests - 46 antigen, 55 PCR and 26 Antibody/serology (https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/medical-devices/authorized/list.html),
and lastly....
(6) Could mean Manufacturing & Production jobs back into Canada from a Canadian-based COVID-19 test maker.